POLE Mutations in Endometrial Cancer

by Jason Wasserman MD PhD FRCPC
March 27, 2026

A POLE mutation is one of the most important findings a pathologist can report in an endometrial cancer — not because it signals danger, but because it signals the opposite. Endometrial cancers with a pathogenic POLE mutation belong to the molecular group with the best prognosis of all four endometrial cancer subtypes. These cancers rarely come back after surgery, even when they look worrying under the microscope. Understanding a POLE result can be genuinely reassuring, and it has direct consequences for how much treatment you may or may not need after surgery.

What POLE is and what it does

POLE is a gene that provides instructions for making a protein called DNA polymerase epsilon. This protein has two jobs: it helps copy the cell’s DNA when a cell divides, and — crucially — it also proofreads that copy, checking for errors and correcting them before they become permanent. Think of it as a photocopier with a built-in quality-control checker.

When the POLE gene carries a specific type of mutation in the part of the protein responsible for proofreading, the quality-control function is lost. The photocopier keeps running, but the checker is switched off. Every time the cancer cell divides, errors accumulate without being fixed. This results in a tumour with an extraordinarily high number of mutations — far more than even most other high-mutation cancers. Scientists call this the “ultramutated” phenotype.

Here is the paradox that makes POLE mutations so clinically important: you might expect a tumour with so many mutations to be very aggressive. In fact, the opposite is true. The massive accumulation of mutations makes POLE-mutated cancer cells look extremely abnormal to the immune system, triggering a strong and effective immune response against them. POLE-mutated endometrial cancers are surrounded by large numbers of immune cells that keep them in check, which is why they rarely spread or come back even when they appear high-grade under the microscope.

What counts as a pathogenic POLE mutation

Not every change detected in the POLE gene carries the same clinical significance. The only mutations that confer this excellent prognosis are specific changes located in the exonuclease domain — the part of the protein responsible for proofreading. These are called pathogenic exonuclease domain mutations.

There are five well-established “hotspot” pathogenic mutations in the POLE exonuclease domain, located at positions called codons 286, 297, 411, 456, and 459. A handful of additional mutations at other positions within the domain are also considered pathogenic. Mutations found outside the exonuclease domain, or variants of uncertain significance, do not carry the same favourable meaning.

This distinction matters because your pathology report may describe a POLE variant, but not all POLE variants are equivalent. Your oncologist or pathologist will interpret whether the specific mutation identified is pathogenic — meaning disease-causing in a clinically significant way — and therefore whether your cancer qualifies as POLE-mutated in the prognostic sense.

How common are POLE mutations in endometrial cancer?

Pathogenic POLE mutations are found in approximately 7-12% of endometrial cancers. They occur almost exclusively in endometrioid carcinoma, the most common type of endometrial cancer. They are very rare in serous carcinoma and clear cell carcinoma, though when present in those histological types, the same favourable prognosis applies.

Despite affecting a relatively small proportion of endometrial cancers overall, POLE-mutated cancers are clinically significant because they are disproportionately represented in high-grade tumours. Up to 36% of high-grade endometrioid carcinomas — cancers that would traditionally be considered high risk based on microscopic appearance alone — carry a POLE mutation. This is exactly why molecular testing matters: grade and appearance alone can be misleading in this group.

Why is the test done

To identify which patients can safely have less treatment after surgery

The most important reason to test for POLE mutations is to avoid overtreating patients who do not need it. For decades, many women with high-grade endometrial cancer received radiation therapy, chemotherapy, or both after surgery, based on microscopic features that suggested high risk. We now know that for POLE-mutated cancers, those features are misleading — the cancer is not behaving as aggressively as it looks. With this knowledge, doctors can avoid putting patients through treatment that would not benefit them and would carry unnecessary side effects.

To assign the cancer to the correct molecular group

POLE mutation status is one of the four key tests used to classify endometrial cancer into its molecular groups. Alongside MMR protein testing (for dMMR/MSI-H) and p53 staining, POLE testing is essential for completing the full molecular picture. The four groups — POLE-mutated, MMR-deficient, NSMP, and p53-abnormal — each carry different prognoses and treatment implications. Without POLE testing, a POLE-mutated cancer might be incorrectly assigned to another group, leading to different — and potentially more aggressive — treatment recommendations.

To guide decisions about immunotherapy in advanced disease

Because POLE-mutated tumours carry so many mutations, they tend to attract large numbers of immune cells. This makes them potentially very responsive to immunotherapy drugs called immune checkpoint inhibitors. For the small number of patients with POLE-mutated endometrial cancer that has come back or spread despite initial treatment, immunotherapy is a promising option that is being actively studied in clinical trials.

How the test is performed

POLE mutation testing is a molecular test performed on tumour tissue — usually from a biopsy or from the uterus removed during surgery. No additional procedure is needed; the tissue already collected for diagnosis is sufficient.

The test uses DNA sequencing to identify mutations in the POLE gene, specifically in the exonuclease domain. The most common method is next-generation sequencing (NGS), which can check POLE alongside many other cancer-related genes in a single test. Sanger sequencing — an older but reliable DNA sequencing method — is also used in some laboratories for POLE hotspot testing.

There is no immunohistochemistry test for POLE mutations — unlike the MMR proteins, which can be detected with stains, POLE protein levels do not change in a way that can be detected under the microscope. DNA sequencing is the only reliable method.

How results are reported

Your pathology report will describe the POLE result in the molecular testing or genomic profiling section. Common ways it is reported include:

POLE mutation detected / POLE pathogenic variant detected. A mutation in the exonuclease domain of the POLE gene was found and has been assessed as pathogenic (disease-causing). The specific mutation will be named — for example, “POLE p.P286R” or “POLE p.V411L.” This result places your cancer in the POLE-mutated molecular group.
POLE wild-type / no pathogenic POLE mutation detected. No pathogenic mutation was found in the POLE exonuclease domain. This is the result in approximately 88 to 93% of endometrial cancers.
POLE variant of uncertain significance (VUS). A change was detected in the POLE gene, but it is not yet known whether this specific variant is pathogenic or benign. A variant of uncertain significance does not carry the same favourable prognosis as a confirmed pathogenic mutation, and your oncologist will interpret it cautiously.

Some reports will also note the tumour’s mutation count or mutational burden alongside the POLE result — POLE-mutated tumours characteristically have very high numbers of mutations, which is consistent with the diagnosis.

What the result means

POLE wild-type (no pathogenic mutation found)

This is the result for the majority of patients. It means POLE testing has not identified a mutation that alters the cancer’s molecular group assignment. Your cancer’s prognosis and treatment plan will be guided by the MMR and p53 results and by the overall stage and grade. The absence of a POLE mutation is not a negative finding — it simply means this particular favourable feature is not present.

POLE pathogenic mutation detected

A confirmed pathogenic POLE mutation places your cancer in the POLE-mutated molecular group, which carries the best prognosis of all four groups. This finding has several important implications:

The outlook is excellent. Fewer than 3% of POLE-mutated endometrial cancers recur. In major clinical trials, patients with POLE-mutated cancers had 10-year recurrence-free survival rates of approximately 98%, regardless of adjuvant treatment. This is a profoundly reassuring finding.
The cancer may look more worrying than it actually is. POLE-mutated cancers are often high-grade under the microscope. They may show features such as lymphovascular space invasion — features that in other molecular groups would indicate a higher risk of recurrence. For POLE-mutated cancers specifically, these features do not predict outcomes in the usual way. This is one of the most important reasons for molecular testing: it corrects the false impression of high risk that the microscopic appearance alone might create.
Less treatment after surgery is likely appropriate. Current European guidelines (ESGO/ESTRO/ESP) classify all stage I and II POLE-mutated endometrial cancers as low-risk, with no adjuvant therapy recommended. This has been supported by multiple clinical trials, most recently by the PORTEC-4a phase III trial (published 2025), which found no recurrences in POLE-mutated stage I and II patients who received no adjuvant treatment. A POLE mutation, therefore, may spare you from radiation therapy and/or chemotherapy that would otherwise be recommended based on grade and stage alone.
The FIGO 2023 staging system recognises POLE mutations. The updated international staging system for endometrial cancer incorporates POLE mutation status directly. Stage I and II endometrial cancers with a confirmed POLE mutation are now reclassified as Stage IAmPOLEmut, regardless of grade, lymphovascular space invasion, or histological type — acknowledging that the standard staging criteria overestimate risk in this group.

What about more advanced POLE-mutated cancers?

Most POLE-mutated endometrial cancers are found at an early stage precisely because they tend not to spread or cause aggressive symptoms. However, a small number are diagnosed at stage III or IV (cancer that has spread beyond the uterus). Even in these cases, outcomes are generally better than those for p53-abnormal cancers at the same stage, and the evidence supporting treatment de-escalation continues to accumulate. Your oncologist will discuss the appropriate approach for your specific situation, taking into account the stage and any other relevant features. Clinical trials exploring immunotherapy in POLE-mutated advanced and recurrent disease are also underway.

Are POLE mutations inherited?

In the vast majority of patients with POLE-mutated endometrial cancer, the mutation is somatic — it arose within the cancer cells during the person’s lifetime and is not present in the rest of the body. It was not inherited and cannot be passed to children. For most patients with a POLE-mutated endometrial cancer, there is no hereditary cancer implication.

However, inherited (germline) POLE mutations do exist, and they can cause a rare hereditary condition called polymerase proofreading-associated polyposis (PPAP). People with PPAP develop multiple colon polyps at a young age and have an increased risk of colorectal cancer and endometrial cancer. PPAP is rare, and it is important not to confuse a somatic POLE mutation found in a tumour with an inherited POLE mutation — they are quite different situations.

Germline POLE mutations are typically suspected when a person develops endometrial or colorectal cancer at a young age, has a strong family history of these cancers, or has multiple colon polyps. If any of these features apply to you, your oncologist may recommend referral to a genetic counsellor to discuss whether germline POLE testing is appropriate. For most women with POLE-mutated endometrial cancer, however, germline testing for POLE is not required as a routine part of their evaluation.

POLE mutations and Lynch syndrome: two separate questions

Patients sometimes wonder whether a POLE mutation and Lynch syndrome are related. They are not — they are entirely separate molecular findings that arise from different causes and carry different implications. Lynch syndrome is caused by an inherited mutation in one of the MMR genes (MLH1, MSH2, MSH6, or PMS2), and it is identified through MMR protein testing. POLE mutations arise in the POLE gene’s proofreading domain and are almost always somatic.

It is possible — though uncommon — for a tumour to carry both a POLE mutation and also show MMR deficiency on testing. When both are present, the POLE mutation takes precedence in the molecular classification: the cancer is classified as POLE-mutated, and the associated POLE-mutation prognosis applies. Whether Lynch syndrome evaluation is still needed in this situation depends on the pattern of MMR protein loss and other clinical factors — your oncologist will discuss this with you.

What happens next

If your POLE result has just come back as a pathogenic mutation, you are likely in the process of discussing treatment options after surgery, or your oncologist is reviewing the result before making recommendations.

For early-stage (stage I or II) POLE-mutated endometrial cancer, the most likely recommendation is that no adjuvant radiation or chemotherapy is needed, even if your tumour was high-grade or showed other traditionally high-risk features. Your oncologist will confirm the recommendation after reviewing all aspects of your case.
For advanced-stage POLE-mutated endometrial cancer, treatment decisions are more nuanced. Your oncologist will discuss the options, which may include a less intensive approach than would typically be used for non-POLE-mutated high-grade cancers of the same stage. Clinical trials may also be relevant.
If your POLE result is a variant of uncertain significance, ask your oncologist how this should be interpreted. It does not carry the reassurance of a confirmed pathogenic mutation, and treatment decisions will be based on other features of the tumour.

Receiving a POLE-mutated result can feel confusing — especially if you have been told that your tumour was high-grade or looked worrying under the microscope. It is completely reasonable to ask your oncologist to explain how the POLE result changes the picture compared to what the microscopic findings suggested. That conversation is one of the most important ones you can have about your diagnosis.

Questions to ask your doctor

Was my endometrial cancer tested for POLE mutations, and what was the result?
If a POLE mutation was found, is it confirmed as pathogenic, and which specific mutation is it?
Does the POLE result change how my cancer is staged, or change the treatment recommendations after surgery?
Based on the POLE result, do I still need radiation therapy or chemotherapy after surgery?
My cancer appeared high-grade under the microscope — does the POLE result change what that means for my prognosis?
Should I be concerned about whether this POLE mutation might be inherited? Do I need to see a genetic counsellor?
Are there clinical trials relevant to my POLE-mutated cancer that I should consider?